Muriel Laffargue

Dr. Muriel Laffargue

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
MWMatthias WYMANN
Matthias WYMANN
MZMarketa Zvelebil
Marketa Zvelebil
MLMuriel Laffargue
Muriel Laffargue

1 March 2002 in Immunity
Verified
Journal Article
Closed access
MLMuriel Laffargue
Muriel Laffargue
RCRonan Calvez
Ronan Calvez
PFPeter Finan
Peter Finan
ATAlexandre Trifilieff
Alexandre Trifilieff
MBMaryse Barbier
Maryse Barbier
MWMatthias WYMANN
Matthias WYMANN

22 March 2016 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
LDLaurent Duca
Laurent Duca
Sébastien BlaiseSébastien Blaise
Sébastien Blaise
BRBéatrice Romier
Béatrice Romier
MLMuriel Laffargue
Muriel Laffargue
SGStéphanie Gayral
Stéphanie Gayral
Pascal MauricePascal Maurice
Pascal Maurice
Cardiovascular diseases (CVDs) are the leading cause of death worldwide and represent a major problem of public health. Over the years, life expectancy has considerably increased throughout the world, and the prevalence of CVD is inevitably rising with the growing ageing of the population. The normal process of ageing is associated with progressive deterioration in structure and function of the vasculature, commonly called vascular ageing. At the vascular level, extracellular matrix (ECM) ageing leads to molecular alterations in long half-life proteins, such as elastin and collagen, and have critical effects on vascular diseases. This review highlights ECM alterations occurring during vascular ageing with a specific focus on elastin fragmentation and also the contribution of elastin-derived peptides (EDP) in age-related vascular complications. Moreover, current and new pharmacological strategies aiming at minimizing elastin degradation, EDP generation, and associated biological effects are discussed. These strategies may be of major relevance for preventing and/or delaying vascular ageing and its complications.

15 July 2010 in The Journal of Immunology
Verified
Journal Article
Closed access
BCBertrand Calippe
Bertrand Calippe
VDVictorine Douin-Echinard
Victorine Douin-Echinard
LDLaurent Delpy
Laurent Delpy
MLMuriel Laffargue
Muriel Laffargue
KLKarine Lélu
Karine Lélu
PGPierre Gourdy
Pierre Gourdy
17β-estradiol (E2) has been shown to promote the expression of inflammatory mediators by LPS-activated tissue resident macrophages through estrogen receptor α (ERα) signaling. However, it remained to be determined whether E2 similarly influences macrophages effector functions under inflammatory conditions in vivo, and whether this action of E2 resulted from a direct effect on macrophages. We show in this study that chronic E2 administration to ovariectomized mice significantly increased both cytokine (IL-1β, IL-6, and TNF-α) and inducible NO synthase mRNA abundance in thioglycolate (TGC)-elicited macrophages. The proinflammatory action of E2 was also evidenced at the level of released IL-1β and IL-6 by ex vivo LPS-activated macrophages. E2 concomitantly inhibited PI3K activity as well as Akt phosphorylation in TGC-elicited macrophages, suggesting that E2 promoted TLR-dependent macrophage activation by alleviating this suppressive signaling pathway. Indeed, this effect was abolished in the presence of the inhibitor wortmannin, demonstrating a key functional link between inhibition of PI3K activity and the E2 action on macrophage functions. Endogenous estrogens levels circulating in ovary-intact mice were sufficient to promote the above described actions. Finally, thanks to a CreLox strategy, targeted disruption of ERα gene in macrophages totally abolished the effect of E2 on the expression of inflammatory mediators by both resident and TGC-elicited peritoneal macrophages. In conclusion, we demonstrate that estrogens, through the activation of ERα in macrophages in vivo, enhance their ability to produce inflammatory mediators and cytokines upon subsequent TLR activation.

21 July 2017 in Circulation Research
Verified
Journal Article
Closed access
AGAlessandra Ghigo
Alessandra Ghigo
MLMuriel Laffargue
Muriel Laffargue
MLMingchuan Li
Mingchuan Li
EHEmilio Hirsch
Emilio Hirsch
Receptor signaling relays on intracellular events amplified by secondary and tertiary messenger molecules. In cardiomyocytes and smooth muscle cells, cyclic AMP (cAMP) and subsequent calcium (Ca 2+ ) fluxes are the best characterized receptor-regulated signaling events. However, most of receptors able to modify contractility and other intracellular responses signal through a variety of other messengers, and whether these signaling events are interconnected has long remained unclear. For example, the PI3K (phosphoinositide 3-kinase) pathway connected to the production of the lipid second messenger PIP3/PtdIns(3,4,5)P3 (phosphatidylinositol (3,4,5)-trisphosphate) is potentially involved in metabolic regulation, activation of hypertrophy, and survival pathways. Recent studies, highlighted in this review, started to interconnect PI3K pathway activation to Ca 2+ signaling. This interdependency, by balancing contractility with metabolic control, is crucial for cells of the cardiovascular system and is emerging to play key roles in disease development. Better understanding of the interplay between Ca 2+ and PI3K signaling is, thus, expected to provide new ground for therapeutic intervention. This review explores the emerging molecular mechanisms linking Ca 2+ and PI3K signaling in health and disease.

9 July 2001 in The FASEB Journal
Verified
Journal Article
Closed access
EHEmilio Hirsch
Emilio Hirsch
OBOrnella Bosco
Ornella Bosco
PTPhilippe Tropel
Philippe Tropel
MLMuriel Laffargue
Muriel Laffargue
RCRonan Calvez
Ronan Calvez
GMGiuseppe Montrucchio
Giuseppe Montrucchio